Morgan Stanley set a $120.00 price target on AveXis (NASDAQ:AVXS) in a research note published on Friday, January 5th. The firm currently has a buy rating on the stock.
A number of other equities analysts also recently weighed in on the stock. UBS Group set a $122.00 price target on shares of AveXis and gave the stock a buy rating in a research note on Friday, January 5th. Citigroup set a $132.00 price target on shares of AveXis and gave the stock a buy rating in a research note on Friday, January 5th. Canaccord Genuity set a $110.00 price objective on shares of AveXis and gave the stock a hold rating in a report on Wednesday, December 20th. BidaskClub upgraded shares of AveXis from a sell rating to a hold rating in a report on Thursday, December 21st. Finally, ValuEngine cut shares of AveXis from a hold rating to a sell rating in a report on Friday, December 1st. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of Buy and an average target price of $113.89.
Shares of AveXis (AVXS) traded up $4.75 during trading hours on Friday, reaching $113.71. 1,140,000 shares of the company’s stock traded hands, compared to its average volume of 663,285. AveXis has a 52 week low of $52.18 and a 52 week high of $119.00. The firm has a market cap of $3,911.01, a P/E ratio of -20.38 and a beta of 2.46.
AveXis (NASDAQ:AVXS) last announced its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.04). During the same quarter in the prior year, the business earned ($0.87) EPS. equities analysts anticipate that AveXis will post -6.23 earnings per share for the current fiscal year.
In related news, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $101.26, for a total value of $180,242.80. Following the completion of the transaction, the vice president now owns 1,780 shares of the company’s stock, valued at $180,242.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP James J. Litalien sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $106.52, for a total transaction of $532,600.00. The disclosure for this sale can be found here. Insiders sold 57,340 shares of company stock valued at $5,851,445 in the last three months. Company insiders own 18.60% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Strs Ohio acquired a new stake in shares of AveXis during the third quarter worth approximately $116,000. Cubist Systematic Strategies LLC increased its holdings in shares of AveXis by 688.6% during the third quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after buying an additional 1,577 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of AveXis during the third quarter worth approximately $200,000. Deschutes Portfolio Strategy LLC acquired a new stake in shares of AveXis during the third quarter worth approximately $203,000. Finally, Ameritas Investment Partners Inc. increased its holdings in shares of AveXis by 331.0% during the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock worth $174,000 after buying an additional 1,622 shares in the last quarter. 92.92% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/28/avexis-avxs-given-a-120-00-price-target-by-morgan-stanley-analysts.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.